The Clinical Research Shared Service (CRSS) participates with members of clinical teams and investigators on all details of clinical trial design, review, implementation, and preparation for quality assurance monitoring, including interactions with the Institutional Review Board of the University of Maryland School of Medicine, the Clinical Research Committee (CRC) (or Protocol Review and Monitoring System) of the University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC), and the Data Safety Monitoring/Quality Assurance Committee of UMGCC. In addition, CRSS participates in negotiating with sponsors to develop budgets for clinical trials in conjunction with the Office of Research and Development at the University of Maryland-Baltimore (UMB). CRSS utilizes and manages the Oncore? database for all patients?completing case report forms for industry-sponsored studies and entering data into appropriate databases for Phase I or Phase 11 trials sponsored by the National Cancer Institute and cooperative group sponsored trials. Oncore? is also utilized for customized case report forms in investigator-initiated protocols. CRSS also collects information and forwards records of underserved minority accrual to clinical trials to Dr. Shana Ntiri, medical director of the Baltimore City Cancer Program, to facilitate periodic reviews in conjunction with CRC. Dr. Ntiri serves as the liaison for clinical research community outreach. During fiscal year 2010 CRSS costs were $3,325,306, of which $280,124 were from the Cancer Center Support Grant and $358,876 were from other peer-reviewed grant support. During the latest 3-year grant period, 37 publications were supported by CRSS, serving the Hormone Responsive Cancers and Experimental Therapeutics Programs at UMGCC.
CRSS is highly relevant to the research mission of UMGCC, because it is the vehicle by which UMGCC delivers possibly life-saving, in some cases, and life-enhancing, in all cases, clinical protocols that represent the current best research questions across the spectrum of clinical cancer research. CRSS provides a uniform order of procedure for clinical research process available to all UMGCC investigators. It actively promotes the inclusion of underserved minorities in the research enterprise of UMGCC.
|NygÃ¥rd, Lotte; Vogelius, Ivan R; Fischer, Barbara M et al. (2016) Early lesion-specific (18)F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer. Radiother Oncol 118:460-4|
|Fox, Jennifer M; Moynihan, James R; Mott, Bryan T et al. (2016) Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs. Oncotarget 7:7268-79|
|Joseph, Ann Mary; Srivastava, Ratika; Zabaleta, Jovanny et al. (2016) Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects. Cancer Immunol Res 4:708-16|
|Zandberg, Dan P; Liu, Sandy; Goloubeva, Olga et al. (2016) Oropharyngeal cancer as a driver of racial outcome disparities in squamous cell carcinoma of the head and neck: 10-year experience at the University of Maryland Greenebaum Cancer Center. Head Neck 38:564-72|
|Doshi, Kshama A; Trotta, Rossana; Natarajan, Karthika et al. (2016) Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress. Oncotarget 7:48280-48295|
|Ambulos Jr, Nicholas P; Schumaker, Lisa M; Mathias, Trevor J et al. (2016) Next-Generation Sequencing-Based HPV Genotyping Assay Validated in Formalin-Fixed, Paraffin-Embedded Oropharyngeal and Cervical Cancer Specimens. J Biomol Tech 27:46-52|
|Temburnikar, Kartik W; Ross, Christina R; Wilson, Gerald M et al. (2015) Antiproliferative activities of halogenated pyrrolo[3,2-d]pyrimidines. Bioorg Med Chem 23:4354-63|
|Kochel, Tyler J; Fulton, Amy M (2015) Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer. Prostaglandins Other Lipid Mediat 116-117:99-103|
|Rasmussen, Jacob H; Vogelius, Ivan R; Aznar, Marianne C et al. (2015) Spatio-temporal stability of pre-treatment 18F-Fludeoxyglucose uptake in head and neck squamous cell carcinomas sufficient for dose painting. Acta Oncol 54:1416-22|
|Shih, Yu-Huan; Zhang, Yuji; Ding, Yonghe et al. (2015) Cardiac transcriptome and dilated cardiomyopathy genes in zebrafish. Circ Cardiovasc Genet 8:261-9|
Showing the most recent 10 out of 207 publications